FY2018 EPS Estimates for AstraZeneca plc Decreased by Analyst (AZN)
AstraZeneca plc (NYSE:AZN) – Analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for AstraZeneca in a research note issued on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will earn $1.78 per share for the year, down from their prior estimate of $1.94. Jefferies Group also issued estimates for AstraZeneca’s FY2019 earnings at $1.88 EPS, FY2020 earnings at $2.19 EPS, FY2021 earnings at $2.68 EPS and FY2022 earnings at $3.21 EPS.
AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.32 EPS.
AstraZeneca (AZN) traded up $0.09 during mid-day trading on Wednesday, reaching $35.08. 2,844,663 shares of the company’s stock were exchanged, compared to its average volume of 3,329,873. The firm has a market cap of $88,380.00, a P/E ratio of 25.06, a price-to-earnings-growth ratio of 3.42 and a beta of 0.76. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a 12 month low of $26.51 and a 12 month high of $35.92.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can increased its holdings in shares of AstraZeneca by 243.4% during the 4th quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after buying an additional 294,246 shares during the last quarter. Clean Yield Group purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $205,000. Private Trust Co. NA purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $310,000. BLB&B Advisors LLC boosted its position in shares of AstraZeneca by 133.8% during the 4th quarter. BLB&B Advisors LLC now owns 54,849 shares of the company’s stock worth $1,903,000 after purchasing an additional 31,388 shares during the period. Finally, Atria Investments LLC boosted its position in shares of AstraZeneca by 26.3% during the 4th quarter. Atria Investments LLC now owns 33,495 shares of the company’s stock worth $1,162,000 after purchasing an additional 6,979 shares during the period. Institutional investors and hedge funds own 14.75% of the company’s stock.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.